Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Nov. 03	Allergan Aesthetics To Present New Research On Aesthetic Care Following Medical Weight Loss And Evolving Patient Needs At ASDS 2026	CI
Oct. 21	Allergan Aesthetics presents its latest scientific advances

Market Cap	63.66B 57.1B 52.18B 47.63B 89.74B 5,984B 92.57B 629B 251B 3,193B 239B 234B 10,080B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 72.62B 66.37B 60.58B 114B 7,611B 118B 800B 319B 4,061B 304B 297B 12,820B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

Nov. 03	Allergan Aesthetics To Present New Research On Aesthetic Care Following Medical Weight Loss And Evolving Patient Needs At ASDS 2026	CI
Oct. 21	Allergan Aesthetics presents its latest scientific advances
Sep. 29	Abbvie Through Allergan Aesthetics Receives Health Canada Authorization for Boey for Frown Lines	CI
Sep. 17	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
Sep. 15	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI
Sep. 01	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
Apr. 07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
Mar. 31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
Mar. 30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
Mar. 19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
Mar. 04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
Nov. 12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25-09-25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI

24-04-01	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
22-04-20	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
22-04-06	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22-03-22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
21-12-10	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

Oct. 21	Allergan Aesthetics présente ses dernières avancées scientifiques
21-04-20	Planète Bourse : La revue de presse du mardi 20 avril 2021
20-05-07	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
20-05-07	La Chine repart, mais Washington veille
20-05-06	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...

Actavis PLC Stock NYSE

Stocks

US00507K1034

Pharmaceuticals

Valuation: Actavis PLC

Latest news: Actavis PLC

Press Releases: Actavis PLC

News in other languages: Actavis PLC

Managers and Directors: Actavis PLC

Other Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Scott Reents BRD	Director/Board Member	-	2020-05-07
Ryan Quigley BRD	Director/Board Member	-	2020-05-07
Andres Rodrigo BRD	Director/Board Member	-	2020-05-07

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.79%	-4.48%	+44.44%	+127.49%	1,206B
JOHNSON & JOHNSON	+1.43%	+1.11%	+47.73%	+82.08%	665B
ABBVIE INC.	+1.07%	-1.21%	+32.99%	+106.31%	515B
ROCHE HOLDING AG	-0.36%	-3.25%	+47.17%	+64.58%	381B
MERCK & CO., INC.	-0.14%	-1.87%	+71.05%	+40.63%	362B
NOVARTIS AG	-0.78%	-0.52%	+30.57%	+57.98%	307B
ASTRAZENECA PLC	-0.80%	-0.21%	+8.54%	+35.56%	289B
AMGEN INC.	+0.03%	-1.20%	+45.89%	+68.76%	249B
GILEAD SCIENCES, INC.	-0.41%	-2.22%	+35.24%	+105.68%	207B
Average	-0.08%	-1.54%	+40.40%	+76.56%	464.42B
Weighted average by Cap.	-0.04%	-1.96%	+42.24%	+88.38%

	2018	2019
Net sales	15.79B 14.16B 12.94B 11.81B 22.26B 1,484B 22.96B 156B 62.2B 792B 59.26B 57.99B 2,500B	16.09B 14.43B 13.19B 12.04B 22.68B 1,512B 23.4B 159B 63.39B 807B 60.39B 59.09B 2,548B
Net income	-5.1B -4.57B -4.18B -3.81B -7.18B -479B -7.41B -50.35B -20.08B -256B -19.13B -18.72B -807B	-5.27B -4.73B -4.32B -3.94B -7.43B -495B -7.67B -52.08B -20.77B -264B -19.78B -19.36B -835B
Net Debt	21.89B 19.63B 17.94B 16.38B 30.86B 2,058B 31.83B 216B 86.24B 1,098B 82.17B 80.4B 3,466B	17.3B 15.52B 14.18B 12.95B 24.4B 1,627B 25.16B 171B 68.17B 868B 64.95B 63.56B 2,740B

End-of-day quote NYSE
- ^USD	-